These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15517893)

  • 1. UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers.
    Oguri T; Takahashi T; Miyazaki M; Isobe T; Kohno N; Mackenzie PI; Fujiwara Y
    Anticancer Res; 2004; 24(5A):2893-6. PubMed ID: 15517893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin.
    Hanioka N; Ozawa S; Jinno H; Ando M; Saito Y; Sawada J
    Xenobiotica; 2001 Oct; 31(10):687-99. PubMed ID: 11695848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
    Jinno H; Tanaka-Kagawa T; Hanioka N; Saeki M; Ishida S; Nishimura T; Ando M; Saito Y; Ozawa S; Sawada J
    Drug Metab Dispos; 2003 Jan; 31(1):108-13. PubMed ID: 12485959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
    Iyer L; King CD; Whitington PF; Green MD; Roy SK; Tephly TR; Coffman BL; Ratain MJ
    J Clin Invest; 1998 Feb; 101(4):847-54. PubMed ID: 9466980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro.
    Takahashi T; Fujiwara Y; Yamakido M; Katoh O; Watanabe H; Mackenzie PI
    Jpn J Cancer Res; 1997 Dec; 88(12):1211-7. PubMed ID: 9473740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
    Gagné JF; Montminy V; Belanger P; Journault K; Gaucher G; Guillemette C
    Mol Pharmacol; 2002 Sep; 62(3):608-17. PubMed ID: 12181437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
    Girard H; Villeneuve L; Court MH; Fortier LC; Caron P; Hao Q; von Moltke LL; Greenblatt DJ; Guillemette C
    Drug Metab Dispos; 2006 Jul; 34(7):1220-8. PubMed ID: 16595709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
    Saito Y; Sai K; Maekawa K; Kaniwa N; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Sawada J
    Drug Metab Dispos; 2009 Feb; 37(2):272-6. PubMed ID: 18981166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
    Liu Y; Ramírez J; House L; Ratain MJ
    Eur J Cancer; 2010 Jul; 46(11):2097-103. PubMed ID: 20580994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms.
    Tallman MN; Ritter JK; Smith PC
    Drug Metab Dispos; 2005 Jul; 33(7):977-83. PubMed ID: 15833930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.
    Ando Y; Saka H; Asai G; Sugiura S; Shimokata K; Kamataki T
    Ann Oncol; 1998 Aug; 9(8):845-7. PubMed ID: 9789606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation.
    Tagawa K; Maruo Y; Mimura Y; Ikushiro S
    Toxicol Mech Methods; 2023 Mar; 33(3):197-205. PubMed ID: 35930428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
    Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
    Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
    Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
    Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of the function of the UDP-glucuronosyltransferase 1A subfamily by cytochrome P450 3A4: different susceptibility for UGT isoforms and UGT1A1/7 variants.
    Ishii Y; Koba H; Kinoshita K; Oizaki T; Iwamoto Y; Takeda S; Miyauchi Y; Nishimura Y; Egoshi N; Taura F; Morimoto S; Ikushiro S; Nagata K; Yamazoe Y; Mackenzie PI; Yamada H
    Drug Metab Dispos; 2014 Feb; 42(2):229-38. PubMed ID: 24255116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
    Jinno H; Saeki M; Saito Y; Tanaka-Kagawa T; Hanioka N; Sai K; Kaniwa N; Ando M; Shirao K; Minami H; Ohtsu A; Yoshida T; Saijo N; Ozawa S; Sawada J
    J Pharmacol Exp Ther; 2003 Aug; 306(2):688-93. PubMed ID: 12730278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Insights into SN-38 Glucuronidation: Evidence for the Important Role of UDP Glucuronosyltransferase 1A9.
    Xiao L; Zhu L; Li W; Li C; Cao Y; Ge G; Sun X
    Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):424-428. PubMed ID: 29076612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
    Nagar S; Blanchard RL
    Drug Metab Rev; 2006; 38(3):393-409. PubMed ID: 16877259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
    Paoluzzi L; Singh AS; Price DK; Danesi R; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    J Clin Pharmacol; 2004 Aug; 44(8):854-60. PubMed ID: 15286088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
    Brangi M; Litman T; Ciotti M; Nishiyama K; Kohlhagen G; Takimoto C; Robey R; Pommier Y; Fojo T; Bates SE
    Cancer Res; 1999 Dec; 59(23):5938-46. PubMed ID: 10606239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.